Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 4/20 | 0.56 |
| ▸ | PLAU | P00749 | 2/20 | 0.55 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | GRB7 | Q14451 | 2/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.48 |
| ▸ | KLK2 | P20151 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25457756 | 1.00 | CTSG (0.56) | CTSGPLAUEPHA2CACNA1BGRB7 | |
| SCHEMBL25455401 | 0.84 | KLKB1 (0.52) | CTSGPLAUKLKB1 | |
| SCHEMBL25455264 | 0.84 | KLKB1 (0.52) | CTSGPLAUKLKB1 | |
| SCHEMBL25455286 | 0.82 | KLKB1 (0.52) | CTSGPLAUEPHA2CACNA1BKLKB1 | |
| SCHEMBL25455467 | 0.80 | KLKB1 (0.45) | CTSGPLAUEPHA2CACNA1BKLKB1 | |
| SCHEMBL25457750 | 0.80 | KLKB1 (0.45) | CTSGPLAUEPHA2CACNA1BKLKB1 | |
| SCHEMBL25455455 | 0.80 | EPHA2 (0.45) | CTSGPLAUEPHA2CACNA1BGRB7 | |
| SCHEMBL25455263 | 0.80 | KLKB1 (0.52) | CTSGKLKB1KLK2ST14 | |
| SCHEMBL25455481 | 0.79 | CTSG (0.54) | CTSGPLAUCACNA1BKLKB1KLK2 | |
| SCHEMBL25455440 | 0.79 | KLHL20 (0.54) | PLAUKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | QUANTUM INTELLIGENCE CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | ITGB7, ITGAM, ITGA4 | CTSG 2091/4885PLAU 793/4885EPHA2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.